Gilenya Now Approved in Europe to Treat Children, Adolescents with RRMS
News
Gilenya (fingolimod) was approved by the European Commission as a treatment for children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS), Novartis announced. The therapy is ... Read more